Table 3.

Published clinical trials with BM-MNC therapy in stroke patients.

Author	Cell population	Number of patients treated (controls)	Design	Route	Cell dose	Time window	Follow-up (months)	Adverse events
Suárez-Monteagudo et al. [14]	Autologous	5 (0)	Open-label phase I	Intraparenchymal	1.4–5.5 × 107	1–10 years	12	Headache, drowsiness, nausea, fever
Savitz et al. [11]	Autologous	10 (0)	Open-label phase I	Intravenous	7–10 × 106/kg	24–72 hours	6	None study-related reported
Friedrich et al. [15]	Autologous	20 (0)	Open-label phase I	Intra-arterial	2.2 × 107	3–7 days	6	None study-related reported
Moniche et al. [7]	Autologous	10 (10)	Observer-blinded phase I/II	Intra-arterial	16 × 107	5–9 days	6	Seizures (2 of 10)
Prasad et al. [16]	Autologous	11 (0)	Open-label phase I	Intravenous	0.2–18 × 107	7–30 days	6	One reinfarction
Li et al. [17]	Autologous	60 (40)	Observer-blinded phase I/II (hemorrhagic stroke)	Intraparenchymal	0.2–2 × 107	5–7 days	6	Fever, one unspecified pulmonary tumor
Barbosa da Fonseca et al. [18], Battistella et al. [8], Rosado-de-Castro et al. [9]	Autologous	12 (0)	Open-label phase I	Intravenous (n = 5), intra-arterial (n = 7)	10–50 × 107	19–89 days	6	Seizures (7 of 12)
Prasad et al. [10]	Autologous	85 (35)	Blinded randomized phase II	Intravenous	28 × 107	18.5 days	12	None reported
Sharma et al. [19]	Autologous	24 (0)	Open-label phase I/II (ischemic and hemorrhagic stroke)	Intrathecal	1 × 106/kg	40 months	30	None reported
Taguchi et al. [20]	Autologous	12 (0)	Open-label phase I/II	Intravenous	29 × 107	7–10 days	6	One recurrent stroke